For PatientsPrescribing InformationProvider Login
hero-drop-mobile
THE FIRST AND ONLY
FDA-approved eye drop for adults with low-lying eyelids
Meet Upneeq

Upneeq lifts tired-looking eyelids fast

Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, is the first and only FDA-approved prescription eye drop for your adult patients with low-lying eyelids (also known as acquired blepharoptosis or ptosis). It provides a non-surgical eyelid lift, quickly lifting eyelids and opening the eyes wider.

Just one drop per eye, once daily, is clinically proven to give your patients visible results — lifted and open eyelids in as fast as 5 minutes that can last up to 8 hours.

No more tired-looking eyes, Upneeq can provide your patients with more awake-looking eyes. Introduce your patients to the eye drop that lifts.

BEFORE
AFTER
After
Before

Actual patient. Individual results may vary. Average upper eyelid lift with Upneeq in clinical studies was 1 mm.

Treat patients with low-lying eyelids

Get Your Patients Started Today

Benefits of Upneeq

Visible results

When it comes to eyelids, a little lift goes a long way. Upneeq provides a non-surgical eyelid lift for your patients that is clinically proven to lift and open upper eyelids.

Fast-acting, long-lasting

Just one drop in each eye can temporarily lift your patient’s upper eyelids in as little as 5 minutes, and last up to 8 hours.

Easy to incorporate

Upneeq comes in single-use vials, and is FDA-approved for once daily use. For your patients, this makes it easy to fit Upneeq into their everyday routines.

Get Your Patients Started

In clinical trials of Upneeq

84%

of patients have had some form of improvement in eyelid lift.

88%

of patients have had some form of improvement in their upper field of vision.

Learn More About Our Story

Delivers rapid, visible lift to the upper eyelid with once-daily use

Mean change from baseline in upper eyelid elevation (MRD-1) after dosing Upneeq (data from pooled analysis of 2 clinical trials) * 1
Mean Change Chart
Upneeq (n=203)
Vehicle (n=101)
Error bars represent standard deviation of the mean change from baseline.
  1. Upneeq increased upper eyelid elevation significantly more than vehicle in clinical trials, as measured by MRD-1 (on Day 1 and Day 14 of treatment). 2
    1. Achieved average eyelid lift of 1mm. 3

  2. In one clinical trial, onset of elevation as shown by improvement in MRD-1 began in some patients 5 minutes after Upneeq was administered (the earliest time point measured). 3
    1. RVL-1201-202, Upneeq (n=109) vs. vehicle (n=55).
MRD-1=Marginal Reflex Distance 1 (distance from the central pupillary light reflex to the central margin of the upper lid).

AS SEEN IN

get-started-section-background-mobile

Give your patients eye-opening results with Upneeq

Get Your Patients Started
Location

Become an Upneeq provider and help patients find your practice

Sign Up as a Provider
References
1. Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020.
2. Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information]. RVL Pharmaceuticals, Inc. 2024.
3. Data on file, RVL Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION


What is UPNEEQ?

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.


What warnings and precautions are associated with UPNEEQ?

  • Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.
  • UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.
  • Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren’s syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse.
  • UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ.
  • Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used.

What are the most common side effects of UPNEEQ?

The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.


What should my doctor know about before prescribing me UPNEEQ?


  • Your doctor should review your full medical history before prescribing UPNEEQ.
  • UPNEEQ belongs to a class of medication (alpha-adrenergic agonists) that may affect your blood pressure. Use UPNEEQ carefully if you currently take an alpha-adrenergic agonist medication to treat heart disease or an enlarged prostate. Patients taking beta-blockers, or other medications to treat hypertension or an abnormal heartbeat, should also be careful when using UPNEEQ.
  • Patients who use a certain class of antidepressant medication (monoamine oxidase inhibitors) should also be careful when using UPNEEQ, as it may affect the way your body absorbs the medication.

These are not all of the possible side effects of UPNEEQ. Tell your doctor if you have any side effect that bothers you or does not go away. Call your doctor for medical advice about side effects.
To report side effects or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report side effects to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.
This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full Prescribing Information for UPNEEQ.

IMPORTANT SAFETY INFORMATION


What is UPNEEQ?

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.


What warnings and precautions are associated with UPNEEQ?

  • Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.
  • UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.
  • Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren’s syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse.
  • UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ.
  • Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used.

What are the most common side effects of UPNEEQ?

The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.


What should my doctor know about before prescribing me UPNEEQ?


  • Your doctor should review your full medical history before prescribing UPNEEQ.
  • UPNEEQ belongs to a class of medication (alpha-adrenergic agonists) that may affect your blood pressure. Use UPNEEQ carefully if you currently take an alpha-adrenergic agonist medication to treat heart disease or an enlarged prostate. Patients taking beta-blockers, or other medications to treat hypertension or an abnormal heartbeat, should also be careful when using UPNEEQ.
  • Patients who use a certain class of antidepressant medication (monoamine oxidase inhibitors) should also be careful when using UPNEEQ, as it may affect the way your body absorbs the medication.

These are not all of the possible side effects of UPNEEQ. Tell your doctor if you have any side effect that bothers you or does not go away. Call your doctor for medical advice about side effects.
To report side effects or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report side effects to the FDA by calling 1-800-FDA-1088 or visit www.fda.gov/medwatch.
This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full Prescribing Information for UPNEEQ.

About UpneeqBefore and AfterWhat is Acquired PtosisResourcesContact Us
Prescribing Information
Privacy PolicyTerms of Use
FacebookTikTokInstagram

Distributed by: RVL Pharmaceuticals, Inc. Bridgewater, NJ 08807.©2024 RVL Pharmaceuticals, Inc. All rights reserved. PM-US-UPN-1709 01/25

Upneeq® is a registered trademark of RVL Pharmaceuticals, Inc.